Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

455 results

• Assessment of KAN-101 in Celiac Disease (ACeD): Complete Statistical AnalysisIndependent statistical analysis of Assessment of KAN-101 in Celiac Disease (ACeD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04248855).Phase 1Results postedn = 41NCT04248855
• Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070): Complete Statistical AnalysisIndependent statistical analysis of Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 17NCT01512693
• ASSUREIndependent statistical analysis of Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 49NCT02750501
• ASTRAL-5Independent statistical analysis of Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection: primary endpoint results,…Phase 3Results postedn = 107NCT02480712
• Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 3NCT05776875
• Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase EARLY_1Results postedn = 24NCT02726542
• AURORAComplete statistical analysis of the phase 3 AURORA trial of cenicriviroc for liver fibrosis in adults with nonalcoholic steatohepatitis, including trial design, registered endpoints, Cochran-Mantel-Haenszel analyses, effect measures, safety, and statistical interpretation.Phase 3Results postedn = 1,778NCT03028740
• Autologous Cell Therapy for Treatment of Fecal Incontinence: Complete Statistical AnalysisIndependent statistical analysis of Autologous Cell Therapy for Treatment of Fecal Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01600755).Phase 1/2Results postedn = 53NCT01600755
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 16NCT03610490
• Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02625623).Phase 3Results postedn = 371NCT02625623
• Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia: Complete Statistical AnalysisIndependent statistical analysis of Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04652479).Phase 2Results postedn = 25NCT04652479
• AXELIndependent statistical analysis of An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 882NCT01696695
• Azacitidine and CAPOX in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and CAPOX in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01193517).Phase 1/2Results postedn = 26NCT01193517
• Azacitidine and Pembrolizumab in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Pembrolizumab in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264404).Phase 2Results postedn = 36NCT03264404
• Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: Complete Statistical AnalysisIndependent statistical analysis of Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04884308).Phase 2Results postedn = 30NCT04884308
• Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy: Complete Statistical AnalysisIndependent statistical analysis of Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04658784).Phase NAResults postedn = 72NCT04658784
• BARIIndependent statistical analysis of Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 14NCT03294850
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 217NCT04579380
• BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326495).Phase 2Results postedn = 51NCT00326495
• BCC-RAD-13Independent statistical analysis of Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 5NCT02128100
• BEe-HIVeIndependent statistical analysis of B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 638NCT04193189
• BEGSIndependent statistical analysis of Benralizumab for Eosinophilic Gastritis (BEGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03473977).Phase 2/3Results postedn = 26NCT03473977
• Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 17NCT03641313
• Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00055692).Phase 2Results postedn = 46NCT00055692
• Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: Complete Statistical AnalysisIndependent statistical analysis of Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 22NCT01879735
• Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 6NCT04390243
• Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 61NCT05265247
• Biomarkers of Intestinal Mucosal Healing in Crohn’s Disease (P08143): Complete Statistical AnalysisIndependent statistical analysis of Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01349920).Phase NAResults postedn = 15NCT01349920
• BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults: Complete Statistical AnalysisIndependent statistical analysis of BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,020NCT02819297
• BLINKIndependent statistical analysis of Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD…Phase NAResults postedn = 187NCT03241368
• C_ASCENTIndependent statistical analysis of Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 46NCT02194998
• C. Difficile and Ursodiol: Complete Statistical AnalysisIndependent statistical analysis of C. Difficile and Ursodiol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02748616).Phase 4Results postedn = 9NCT02748616
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 109NCT02867592
• CADDIEIndependent statistical analysis of CADDIE Trial - Computer Aided Diagnosis and Detection for Intelligent Endoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 739NCT04325815
• Cap-assisted Water Immersion Versus Water Immersion Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Cap-assisted Water Immersion Versus Water Immersion Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01547247).Phase NAResults postedn = 208NCT01547247
• Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 133NCT02873195
• Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00565370).Phase 1/2Results postedn = 22NCT00565370
• Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 12NCT00891878
• Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 50NCT00416494
• CAPYBARAIndependent statistical analysis of A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 22NCT05479058
• CARESIndependent statistical analysis of Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05714644).Phase NAResults postedn = 5,127NCT05714644
• CASEIIIndependent statistical analysis of Cytosponge Adequacy Study Evaluation II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02395471).Phase NAResults postedn = 191NCT02395471
• Catheter Placement for Hepatic Hydrothorax: Complete Statistical AnalysisIndependent statistical analysis of Catheter Placement for Hepatic Hydrothorax: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02595567).Phase NAResults postedn = 25NCT02595567
• CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00540579).Phase 1/2Results postedn = 23NCT00540579
• CDI-SCOPEIndependent statistical analysis of A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection: primary endpoint results, effect estimate with…Phase 3Results postedn = 41NCT05831189
• Cerebral Blood Flow During Propofol Anaesthesia: Complete Statistical AnalysisIndependent statistical analysis of Cerebral Blood Flow During Propofol Anaesthesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02951273).Phase NAResults postedn = 30NCT02951273
• CERTAIN-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 136NCT02723084
• Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 13NCT00538291
• Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 41NCT00319735
• Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 2,334NCT00265850

← All therapeutic areas